Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...
The Cool Down on MSN6d
This ultra-futuristic e-bike packs serious power in the world's smallest frame — here's what you need to seeThe bike has been in development for years. This ultra-futuristic e-bike packs serious power in the world's smallest frame — ...
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback